Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Eli Lilly and Company
  6. Summary
    LLY   US5324571083

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/23/2021 07/26/2021 07/27/2021 07/28/2021 07/29/2021 Date
244.15(c) 243.21(c) 243.58(c) 246.51(c) 245.33(c) Last
2 448 303 2 678 920 2 116 551 1 688 130 1 919 223 Volume
+2.37% -0.39% +0.15% +1.20% -0.48% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 27 265 M - -
Net income 2021 6 579 M - -
Net Debt 2021 11 244 M - -
P/E ratio 2021 33,8x
Yield 2021 1,34%
Sales 2022 27 924 M - -
Net income 2022 7 449 M - -
Net Debt 2022 9 318 M - -
P/E ratio 2022 29,4x
Yield 2022 1,51%
Capitalization 223 B 223 B -
EV / Sales 2021 8,59x
EV / Sales 2022 8,32x
Nbr of Employees 35 000
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products... 
Read more
Sector
Pharmaceuticals
Calendar
08/03Earnings Release
More about the company
Ratings of Eli Lilly and Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ELI LILLY AND COMPANY
03:01pELI LILLY AND : Lilly releases donanemab data that demonstrated relationship bet..
PR
10:57aELI LILLY AND : Incyte Get Expanded Emergency Use Approval for Baricitinib as Mo..
MT
10:02aEli Lilly, Kumquat Biosciences Form Cancer Collaboration
DJ
09:27aELI LILLY AND : FDA broadens existing emergency use of Lilly and Incyte's barici..
PR
09:03aELI LILLY AND : Unit, Kumquat Biosciences to Develop Molecules for Tumor Immunit..
MT
08:04aLilly, Incyte Get Emergency Use Authorization for Covid-19 Treatment as Monot..
DJ
07:49aELI LILLY AND : Unit, Kumquat Biosciences to Develop Molecules to Invoke Tumor I..
MT
06:46aELI LILLY AND : Lilly and Kumquat Biosciences Announce Collaboration to Discover..
PR
07/23ELI LILLY AND : (LLY) sees Significant Insider Selling Continuing
MT
07/23A Guiding Light For The Research Safe Harbor And "Research Tools"?
AQ
07/22ELI LILLY AND : Significant Insider Selling Continues at Eli Lilly (LLY)
MT
07/22INSIDER TRENDS : Insider 90-Day Selling Trend Prolonged at Eli Lilly
MT
07/22ELI LILLY AND : Lilly Confirms Date and Conference Call for Second-Quarter 2021 ..
PR
07/21INSIDER TRENDS : Selling By Insiders Continues at Eli Lilly
MT
07/19TALKSPACE : Hires Jennifer Fulk as CFO
MT
More news
News in other languages on ELI LILLY AND COMPANY
10:28aELI LILLY : EUA élargie pour le baricitinib dans la Covid-19
07/14ELI LILLY : acquisition de Protomer Technologies
07/09ELI LILLY : résultats encourageants pour le mirikizumab
07/06ELI LILLY : résultats positifs dans l'insuffisance cardiaque
06/30ELI LILLY : déclare le dividende du 3e trimestre
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Analysis
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 245,33 $
Average target price 241,90 $
Spread / Average Target -1,40%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY45.30%224 084
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.18.04%243 220
NOVARTIS AG0.39%223 750
ABBVIE INC.10.64%209 386